GRAIL targets over $1 bln Series B
GRAIL, a life sciences company focused on early cancer detection, is planning on raising over $1 billion in Series B funding, according to its parent company Illumina Inc. The investors were not named. Goldman Sachs will serve a a placement agent. GRAIL's previous backers include ARCH Venture Partners, Bezos Expeditions, Bill Gates, Sutter Hill Ventures and GV.
6 January 2017•1 min read
